阿莫奈韦（Amenamevir）

CAS：841301-32-4

质量标准：In House

Status: Pilot validation completed

Amenamevir is an oral antiviral medication developed by Japan's Maruho Co., Ltd. (originally researched by Shionogi and Astellas Pharma). It treats herpes zoster (shingles) and recurrent genital herpes.

Its mechanism of action involves specifically inhibiting the helicase-primase complex, a key enzyme required for herpes virus DNA replication, thereby effectively blocking viral proliferation.

A key advantage is its once-daily oral dosing for shingles, which offers convenience and avoids the need for dose adjustment in patients with renal impairment. It provides a valuable alternative for patients with inadequate response to traditional therapies like acyclovir

阿莫那韦（Amenamevir） 是一种口服抗病毒药物，由 日本Maruho株式会社 研发（原研涉及盐野义、安斯泰来），适用于治疗 带状疱疹和复发性单纯疱疹。

其 作用机制 是特异性抑制疱疹病毒DNA复制所需的 解旋酶-引物酶复合物，从而有效阻断病毒增殖。

该药的主要 优势 在于治疗带状疱疹时 每日仅需口服一次，且 无需因肾功能不全调整剂量，用药便捷，为对传统药物（如阿昔洛韦）应答不足的患者提供了替代选择。